Showing 761 - 780 results of 8,962 for search 'significantly ((((((lower decrease) OR (we decrease))) OR (teer decrease))) OR (larger decrease))', query time: 0.63s Refine Results
  1. 761

    Top-level overview for ADHD classification study. by Ahmed Akib Jawad Karim (20427740)

    Published 2025
    “…Referring to LastBERT, a customized student BERT model, we significantly lowered model parameters from 110 million BERT base to 29 million-resulting in a model approximately 73.64% smaller. …”
  2. 762
  3. 763
  4. 764

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
  5. 765

    Original data2. by Lan Zeng (638254)

    Published 2025
    “…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”
  6. 766

    Original data1. by Lan Zeng (638254)

    Published 2025
    “…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”
  7. 767
  8. 768

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  9. 769

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  10. 770

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  11. 771
  12. 772

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  13. 773

    MXene/Bi<sub>2</sub>O<sub>3</sub> Nanocomposites as Supercapacitors for Portable Electronic Devices by Nanasaheb M. Shinde (8560572)

    Published 2025
    “…2D MXene nanosheets often encounter challenges such as aggregation and restacking, which can significantly decrease their performance in supercapacitor applications. …”
  14. 774
  15. 775
  16. 776
  17. 777
  18. 778
  19. 779
  20. 780